Reata Pharmaceutical announces positive topline results from the MOXIe trial
Ataxia UK is delighted to hear about the positive results Reata just released yesterday from its recent trial in Friedreich’s ataxia (FA). This was a 48-week trial in a number of sites around the world including the London Ataxia Centre testing the effect of Omaveloxolone (Omav).
The results of the study showed that patients taking Omav for 48 weeks had a statistically significant improvement in their symptoms associated with FA than those on the placebo trial (a placebo is a substance that has no therapeutic effect, used as a control in testing new drugs.). Not just a slowing down or halt in progression, but an improvement.
This is a truly incredible result. The management team at Reata have said that Omav has the potential to be the first approved treatment for FA.
The full results of the trial will be presented at a conference soon and we will keep you updated with more information as it becomes available.
Prof Paola Giunti, Head of the London Ataxia Centre, says: “We are excited by these promising results of the trial and hope this will lead to the development of a much-needed approved treatment for Friedreich’s ataxia. I am so grateful to all the people with FA who have taken part in this trial. We are also proud to have contributed to the preclinical study showing the beneficial effects on cell models.”
Dr Julie Greenfield, Head of Research at Ataxia UK, says: “This is very exciting news. Ataxia UK will be following this closely and will make sure you are all kept up to date with latest developments in this research”
For more information you can read the press release here.
Update October 2020 – The results of this trial have now been published (read the abstract here).